Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Probmet Therapeutics logo — An oncology therapeutics company developing new targeted tre...

Probmet Therapeutics

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.

Founded 2022 Denmark Denmark 2 employees Convertible Note Total: $500.00K Health Care, Health and Wellness

General Information

Company Name Probmet Therapeutics
Founded Year 2022
Location Denmark Denmark +1
Employees 2
Industries Health Care, Health and Wellness
Funding Stage Convertible Note
Social

Get notified when Probmet Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Probmet Therapeutics

Probmet Therapeutics, headquartered in Denmark, is making strides in the field of precision oncology with a focus on developing new therapies for metastatic breast cancer in the brain. Founded in 2022, the company operates within the Health Care and Health and Wellness industries. Its core mission revolves around a critical unmet medical need, as existing treatments for breast cancer brain metastases are severely limited.

With a keen focus on innovation, Probmet Therapeutics aims to pioneer targeted treatments that could significantly alter the treatment landscape for patients afflicted by this challenging condition. Their proactive approach attracted a €500.00K Convertible Note investment from the BioInnovation Institute on 15 March 2022. This substantial funding underscores investor confidence in their vision and potential to create impactful therapeutic interventions.

Taxonomy: Oncology Therapeutics, Targeted Treatments, Breast Cancer, Brain Metastasis, Precision Medicine, Metastatic Cancer, Therapeutic Development, Innovation in Cancer Treatment, Breakthrough Therapies, Neuroscience Oncology, Cancer Research, Pharmaceuticals

Services & Products

Targeted Cancer Treatments
Drug Discovery and Development
Clinical Trial Research
Biomarker Strategy

Target Customers

Breast Cancer Patients with Brain Metastasis Oncologists and Clinical Researchers Pharmaceutical and Biotech Companies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 1
Investor
15 Mar 2022

Probmet Therapeutics Alternatives & Competitors

View All Alternatives
Probmet Therapeutics vs
Sermonix Pharmaceuticals
Sermonix Pharmaceuticals United States

Passion and purpose in women’s oncology

Series A
8 employees
Biopharma, Pharmaceutical
Probmet Therapeutics vs
HAVAH Therapeutics
HAVAH Therapeutics Australia

Developing prevention and early treatment options for hormonally driven breast cancer and other brea...

Series Unknown
5 employees
Biotechnology, Health Care
Probmet Therapeutics vs
Phoenix Molecular Designs
Phoenix Molecular Designs United States

A clinical stage biopharmaceutical company designing precise cancer therapeutics to address unmet me...

Series A
22 employees
Biotechnology, Health Care
View all alternatives

FAQ About Probmet Therapeutics

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.
Probmet Therapeutics was founded in 2022.
Probmet Therapeutics is headquartered in Denmark.
Probmet Therapeutics operates in the following industries: Health Care, Health and Wellness.
Probmet Therapeutics has approximately 2 employees.
Probmet Therapeutics has completed 1 funding round, raising a total of $500.00K. The latest funding stage is Convertible Note.
Probmet Therapeutics offers: Targeted Cancer Treatments, Drug Discovery and Development, Clinical Trial Research, Biomarker Strategy.
Top alternatives and competitors to Probmet Therapeutics include Sermonix Pharmaceuticals, HAVAH Therapeutics, Phoenix Molecular Designs, Vyriad, Endocyte. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Probmet Therapeutics and Sermonix Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Probmet Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy